IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Simons *et al.* 09/145,916

Serial No.

Filed For

September 2, 1998
"STIMULATION OF ANGIOGENESIS VIA

ENHANCED ENDOTHELIAL EXPRESSION OF SYNDECAN-4 CORE PROTEINS"

David Guzo

Examiner Group Art Unit

1636

Attorney's Docket No. : BIS-039

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on:_

Attorney for Applicants:

Signature:

Date:

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as mailed October 10, 2001 and extended through February 10, 2002, please find enclosed the following

documents for filing on behalf of applicants and for formal entry into the above-identified application:

- 1. A Second Amendment Of Specification And Request For Entry Of A Second Paper Form Copy Of The Sequence Listing Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.
- 2, A replacement amended paragraph page for the Specification.
- 3. A second paper form copy of the "Sequence Listing" to be formally entered into the original Specification of the aboveidentified patent application.
- 4. A marked-up copy of the replacement amended paragraph page for the Specification pursuant to 37 C.F.R. 121(b).
- A second computer readable form (CRF) copy of the "Sequence" 5. Listing".
- A Second Statement And Verification Of Substantive Identity 6. Between The Second Computer Readable Form (CRF) Copy And The Second Paper Form Copy Of The "Sequence Listing".
- One copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as mailed October 10, 2001.

Respectfully submitted,

SIMONS et al.

2.O. Box 5387

Magnolia, Massachusetts 01930

Tel.: (978) 525-3794

David Prashker

Reg. No. 29,693

Attorney for applicants

GLOUCESTER CO-OPERATIVE BANK DAVID PRASHKER, PC 001970m - 12113702284 000 051 3m 0 2802 DOLLARS () 1970

Applicants' Copy

Application No. 67/1959/

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s): This application clearly fails to comply with the requirements of 37 CFR 1.821 Applicant's attention is directed to these regulations, published at 1114 OC 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on pap r copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing. " The computer readable form that has been filed with this application has be n found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). existed on Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing" An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) For questions regarding compliance with these requirements, please contact: For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212 For PatentIn software h lp, call (703) 557-0400